Reported about 12 hours ago
Gilead Sciences has partnered with Denmark's LEO Pharma to develop treatments for inflammatory diseases, with LEO eligible for up to $1.7 billion in payments, including an initial $250 million. Gilead will obtain global rights to a small molecule oral program targeting STAT6, which shows promise in treating conditions like atopic dermatitis, asthma, and COPD. This partnership is set to impact Gilead's earnings per share for 2025.
Source: YAHOO